NCT06932952 2026-01-16
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors
Byondis B.V.
Phase 1 Active not recruiting
Byondis B.V.
Jacobio Pharmaceuticals Co., Ltd.
Klus Pharma Inc.
Genmab
Allist Pharmaceuticals, Inc.
Eucure (Beijing) Biopharma Co., Ltd
Arch Oncology
Athenex, Inc.
Ipsen
Harbour BioMed (Guangzhou) Co. Ltd.
Merck Sharp & Dohme LLC